Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk

Detalles Bibliográficos
Autores principales: Lesniak, Robert K., Nichols, R. Jeremy, Montine, Thomas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643380/
https://www.ncbi.nlm.nih.gov/pubmed/36388213
http://dx.doi.org/10.3389/fneur.2022.1016040
Descripción
Sumario:

Ejemplares similares